# R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

> **NCT01446900** · PHASE2 · TERMINATED · sponsor: **European Institute of Oncology** · enrollment: 25 (actual)

## Conditions studied

- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cladribine

## Key facts

- **NCT ID:** NCT01446900
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** low rate in patient accrual
- **Last updated:** 2018-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446900, "R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01446900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*